Stephen Basso
Director of Finance/CFO en INNOVIVA, INC. .
Fortuna: 184 343 $ al 31/03/2024
Perfil
Stephen Basso is currently the Chief Financial Officer at Innoviva, Inc. Prior to this, he was the Vice President-North America Commercial at Alexion Pharmaceuticals, Inc. from 2016 to 2017, and the Chief Financial Officer & Senior VP-Finance at Inozyme Pharma, Inc. from 2020 to 2021.
He also served as the Chief Operating & Financial Officer at Cybrexa, Inc. Mr. Basso holds an MBA from Boston College and an undergraduate degree from Providence College.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
INNOVIVA, INC.
0.02% | 05/03/2024 | 12 096 ( 0.02% ) | 184 343 $ | 31/03/2024 |
Cargos activos de Stephen Basso
| Empresas | Cargo | Inicio |
|---|---|---|
| INNOVIVA, INC. | Director of Finance/CFO | 21/08/2023 |
Antiguos cargos conocidos de Stephen Basso.
| Empresas | Cargo | Fin |
|---|---|---|
| INOZYME PHARMA, INC. | Director of Finance/CFO | 14/05/2021 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/05/2017 |
Cybrexa, Inc.
 Cybrexa, Inc. BiotechnologyHealth Technology Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT. | Director of Finance/CFO | - |
Formación de Stephen Basso.
| Boston College | Masters Business Admin |
| Providence College | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| INNOVIVA, INC. | Health Technology |
| INOZYME PHARMA, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Cybrexa, Inc.
Cybrexa, Inc. BiotechnologyHealth Technology Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT. | Health Technology |
- Bolsa de valores
- Insiders
- Stephen Basso
